Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia

International Journal of Urology

Volumn 13, Issue 11, 2006, Pages 1405-1409

  Rahardjo, Djoko ^a   Soebadi, Doddy M ^b   Sugandi, Suwandi ^c   Birowo, Ponco ^a   Djati, Wahjoe ^b   Wahyudi, Irfan ^c  

^a CIPTO MANGUNKUSUMO HOSPITAL   (Indonesia)

^b AIRLANGGA UNIVERSITY   (Indonesia)

^c PADJADJARAN UNIVERSITY   (Indonesia)

Author keywords

Benign prostatic hyperplasia; Doxazosin; Lower urinary tract symptoms; Tamsulosin

Indexed keywords

DOXAZOSIN; TAMSULOSIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEART RATE; HUMAN; INDONESIA; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; RESIDUAL URINE; SYSTOLIC BLOOD PRESSURE; URINARY TRACT DISEASE; URINE FLOW RATE;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; BLOOD PRESSURE; DOXAZOSIN; HEART RATE; HUMANS; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; SULFONAMIDES; TREATMENT OUTCOME; URETHRAL DISEASES; URINARY BLADDER NECK OBSTRUCTION; URODYNAMICS;

EID: 33750473760     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2006.01590.x     Document Type: Article

References (26)

1. Chute CG, Panser LA, Girman CJ et al. The prevalence of prostatism: a population-based survey of urinary symptoms. J. Urol. 1993; 150: 85-9.
2. Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991; 338: 469-71.
3. Clifford GM, Farmer RDT. Medical therapy for benign prostatic hyperplasia: a review of the literature. Eur. Urol. 2000; 38: 2-19.
4. Caine M, Pfau A, Perlberg S. The use of alpha-adrenergic blockers in benign prostatic obstruction. Br. J. Urol. 1976; 48: 255-63.
5. Lepor H. Medical therapy for benign prostatic hyperplasia. Urology 1993; 42: 483-501.
6. Lepor H. The treatment of benign prostatic hyperplasia with alpha1 blockers. Curr. Opin. Urol. 1994; 4: 16-21.
7. Monda JM, Oesterling JE. Medical treatment of benign prostatic hyperplasia: 5 alpha-reductase inhibitors and alpha-adrenergic antagonists. Mayo Clin. Proc. 1993; 68: 670-9.
8. Gillenwater JY, Conn RL, Chrysant SG et al. Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double blind, placebo-controlled, dose-response multicenter study. J. Urol. 1995; 154: 110-15.
9. Lee E. Comparison of tamsulosin and finasteride for lower urinary tract symptom associated with benign prostatic hyperplasia in Korean patients. J. Int. Med. Res. 2002; 30: 584-90.
10. Fawzy A, Braun K, Lewis GP, Gaffney M, Ice K, Dias N. Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. J. Urol. 1995; 154: 105-9.
11. Milani S, Djavan B. Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: latest update on alpha1-adrenoceptor antagonists. BJU Int. 2005; 95: 29-36.
12. Arnold EP. Tamsulosin in men with confirmed bladder outlet obstruction: a clinical and urodynamic analysis from a single centre in New Zealand. BJU Int. 2001; 87: 24-30.
13. Narayan P, Tewari A. A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. United States 93-01 Study Group. J. Urol. 1998; 160: 1701-6.
14. de Reijke TM, Klarskov P. Comparative efficacy of two alpha-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement. BJU Int. 2004; 93: 757-62.
15. Kirby RS, Roehrborn C, Boyle P et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 2003; 61: 119-26.
16. Okada H, Kamidono S, Yoshioka T et al. A comparative study of terazosin and tamsulosin for symptomatic benign prostatic hyperplasia in Japanese patients. BJU Int. 2000; 85: 676-81.
17. Tsujii T. Comparison of prazosin, terazosin and tamsulosin in the treatment of symptomatic benign prostatic hyperplasia: a short-term open, randomized multicenter study. Int. J. Urol. 2000; 7: 199-205.
18. Li NC, Chen S, Yang XH, Du LD, Wang JY, Na YQ. Efficacy of low dose tamsulosin in Chinese patients with symptomatic benign prostatic hyperplasia. Clin. Drug Invest. 2003; 23: 781-7.
19. Eri LM, Tveter KJ. Alpha-blockade in the treatment of symptomatic benign prostatic hyperplasia. J. Urol. 1995; 154: 923-34.
20. Lepor H. Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Urology 1998; 51: 901-6.
21. Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Urology 1998; 51: 892-900.
22. Schulman CC, Lock TM, Buzelin JM et al. Long-term use of tamsulosin to treat lower urinary tract symptom/benign prostatic hyperplasia. J. Urol. 2001; 166: 1358-63.
23. Gillenwater JY, Conn RL, Chrysant SG et al. Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter study. J. Urol. 1995; 154: 110-15.
24. Kaplan SA, Kaplan NM. Alpha-blockade: monotherapy for hypertension and benign prostatic hyperplasia. Urology 1996; 48: 541-50.
25. Kaplan SA, D'alisera PM, Quinones S, Soldo KA. Doxazosin in physiologically and pharmacologically normotensive men with benign prostatic hyperplasia. Urology 1995; 46: 512-17.
26. Mann RD, Biswas P, Freemantle S, Pearce G, Wilton L. The pharmacovigilance of tamsulosin: event data on 12 484 patients. BJU Int. 2000; 85: 446-50.